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Abstract: Thyroid disease mainly has a thyroid origin but can occasionally have a pituitary origin.
Clinicians face several challenges when these conditions occur together. We aimed to determine
the prevalence of thyroid disorders in patients undergoing trans-sphenoidal adenomectomy (TSA)
for pituitary disease. We reviewed the medical records of patients undergoing TSA for pituitary
disease between 2008 and 2017 at Severance Hospital. Thyroid disorders were categorized using
blood test results and medical histories at the time of preoperative evaluation. Among 2202 patients,
44 (2%), 218 (9.9%), and 74 (3.4%) had hyperthyroidism, hypothyroidism, and post-thyroidectomy
status before TSA, respectively. Among the 44 patients with hyperthyroidism, 30 (68.2%) had
central hyperthyroidism. Among the 218 patients with hypothyroidism, 165 (75.7%) had central
hypothyroidism. Central hypothyroidism was more common in patients with adrenocorticotropic
hormone-secreting pituitary adenomas (aOR (adjusted odds ratio) 1.85), Rathke’s cleft cysts (aOR 2.34),
and craniopharyngiomas (aOR 2.58) (all p < 0.05) than in those with nonfunctioning pituitary
adenomas. Contrastingly, thyroid cancer had an increased prevalence in patients with growth
hormone- (aOR 3.17), prolactin- (aOR 3.66), and thyroid-stimulating hormone-secreting (aOR 6.28)
pituitary adenomas (all p < 0.05). Pituitary disease sometimes accompanies thyroid disorders; their
characteristics vary according to the type of pituitary disease.
Keywords: prevalence; thyroid disease; hypothyroidism; hyperthyroidism; thyroid cancer;
pituitary disease
1. Introduction
The thyroid gland produces thyroid hormones that play a critical role in maintaining thermogenic
and metabolic homeostasis. Thyroid hormone output is regulated by the thyroid-stimulating hormone
(TSH) secreted by the anterior pituitary gland; TSH is regulated by the thyrotropin-releasing hormone
(TRH) produced by the hypothalamus [1]. Therefore, thyroid disorders can be caused by a defect
anywhere in the hypothalamic-pituitary-thyroid axis.
Thyroid function tests, used to evaluate the cause of thyroid disease [2], are common in
clinical settings. In most cases, interpreting thyroid function tests that evaluate free thyroxine
(fT4), triiodothyronine (T3), and TSH is straightforward. However, there are still important pitfalls and
difficult cases. Sometimes it is difficult to distinguish between a pituitary-origin and thyroid-origin
thyroid disorder, especially when pituitary and thyroid diseases occur together. Although central
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hyperthyroidism and hypothyroidism are rare diseases, this difficulty can raise several challenges
for clinicians [3,4]. In addition, in cases involving pituitary disease, physicians tend to focus on the
pituitary problem, neglecting the thyroid disease, even though the treatments and prognoses for both
conditions are different.
Recently, there have been reports of thyroid cancer coexisting with TSH-secreting [5] or growth
hormone (GH)-secreting pituitary adenomas [6]. However, although pituitary disease may affect
thyroid cancer development, the rarity of the disease limits further study.
We aimed to investigate the prevalence of thyroid disease in patients who underwent
trans-sphenoidal adenomectomy (TSA) for pituitary disease.
2. Experimental Section
2.1. Patients
We reviewed the medical records of patients who underwent TSA for pituitary disease from
2008 to 2017 at Severance Hospital, of whom 2202 patients were enrolled. Data on age, sex, and
current medications were recorded. Medical histories were taken for all patients scheduled for TSA
in our institute. At the same time, medical records from other institutes and information on current
medications were also collected. History of thyroid disease was documented from the obtained hospital
records. All thyroid disorders, including thyroid abnormalities (based on blood test results or medical
histories at preoperative evaluation), were confirmed by an endocrinologist before TSA.
TSA for each classification of pituitary adenomas was performed according to clinical guidelines [7–11].
In brief, all patients with GH-secreting pituitary adenomas, Cushing’s disease, and TSH-secreting
pituitary adenomas received TSA, except for cases of contraindication of general anesthesia.
For prolactinoma, TSA was performed when dopamine agonists were ineffective in normalizing
prolactin levels or when they led to intolerable side effects. Furthermore, patients with prolactinoma
who preferred surgical resection to medical treatment or who desired to become pregnant soon received
TSA. Lastly, clinically nonfunctioning pituitary adenomas and Rathke’s cleft cysts were surgically
removed in cases where visual field defects were caused, thus approaching towards optic chiasm or
enlarging progressively. This study was conducted in accordance with the 1964 Declaration of Helsinki
and was approved by our institutional review board (No. 4-2018-0582); the need for informed consent
was waived because of the retrospective nature of the study.
2.2. Definitions of the Diseases
Serum TSH (normal range, 0.35-4.94 µIU/mL), fT4 (normal range, 0.70–1.48 ng/dL), and T3
(normal range, 0.58–1.59 ng/mL) levels were measured using a microparticle chemiluminescence
immunoassay (Abbott Ireland Diagnostics Division, Longford, Ireland). TSH receptor (TSHR)
antibody (normal range, 0–1.75 IU/L) levels were measured using a third-generation TBII
electrochemiluminescence immunoassay (Elecsys/Cobas; Roche Diagnostics, Mannheim, Germany) [12]
in patients with hyperthyroidism.
Thyroid diseases were categorized into five groups: primary hyperthyroidism, central
hyperthyroidism, primary hypothyroidism, central hypothyroidism, and post-thyroidectomy status.
Primary hyperthyroidism was defined as a low TSH level with high fT4 (or T3) levels or current use of
medication, including propylthiouracil, methimazole, or carbimazole, after confirmed TSHR antibody
elevation. Based on the presence or absence of elevated TSHR antibody levels, primary hyperthyroidism
was reclassified as Graves’ disease or transient thyrotoxicosis. Transient thyrotoxicosis was defined
as a low TSH level with high fT4 (or T3) levels; (1) without evidence of thyroid autoimmunity, (2) a
lack of Graves’ disease physical findings, and (3) spontaneous resolution. Central hyperthyroidism
was defined as a normal or high TSH level with high fT4 (or T3) levels. Primary hypothyroidism was
defined as a high TSH level with low fT4 (or T3) levels or a use of thyroid hormones (levothyroxine,
liothyronine, or a combination of levothyroxine and liothyronine) for more than 6 months, in order to
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exclude patients with transient or central hypothyroidism. Central hypothyroidism was defined as
low fT4 (or T3) levels without TSH elevation. Post-thyroidectomy status was separately defined as a
medical history of thyroidectomy due to a benign or cancerous lesion. If medical history or thyroid
function test results were ambiguous, such as in cases of iatrogenic thyrotoxicosis, the disease category
was decided by two endocrinologists (Daham Kim and Yongin Cho). Cases of subclinical thyroid
dysfunction, such as subclinical hyperthyroidism and subclinical hypothyroidism, were not defined
as a disease category because origins of such cases were often unclear with respect to the presence
of pituitary disease. In these cases, we followed up with regular thyroid function tests according to
guidelines and considered further workup or treatment as necessary. Patients with GH adenomas
who received preoperative treatment of somatostatin analogues underwent TSA after 3 months of last
somatostatin analogues injection.
The diagnosis of pituitary disease was based on clinical and pathological findings. Most pituitary
diseases were pituitary adenomas; other disorders, such as Rathke’s cleft cysts and craniopharyngiomas,
were rare. Patients with GH adenomas further underwent thyroid ultrasonography due to the possibility
of an increased incidence of thyroid cancer in patients of acromegaly.
2.3. Statistical Analysis
SPSS Statistics Version 23 (IBM Corp., Armonk, NY, USA) was used for all statistical analyses.
The analyses of current study are retrospective and exploratory, and we did not calculate the sample size
for our analyses. Categorical variables were presented as numbers and percentages, and continuous
variables were presented as means ± standard deviations. The two-sample Student’s t-test was used to
compare mean values; group comparisons were performed using the χ2 test, Fisher’s exact test, or
linear-by-linear association, as appropriate. Multiple logistic regression analysis was performed to
evaluate the differences in thyroid disease prevalence according to the type of pituitary disease. Age
and sex were calibrated in adjusted models. Adjusted odds ratios (aORs) and 95% confidence intervals
(CIs) were determined. p-values of <0.05 were considered statistically significant.
3. Results
3.1. Prevalence of Thyroid Disease Before TSA
A total of 2202 patients (885 (40.2%) men and 1317 (59.8%) women) underwent TSA for pituitary
disease during the study period. The mean age was 45 years. Among the 2202 patients, 44 had
hyperthyroidism, whereas 218 had hypothyroidism. Among the 44 patients with hyperthyroidism,
9 (20.4%) were confirmed to have Graves’ disease, and 5 (11.4%) were confirmed to have transient
thyrotoxicosis. There was no toxic multinodular goiter or toxic adenoma case in this study. Among the
218 patients with hypothyroidism, 53 (24.3%) were confirmed to have primary hypothyroidism. Central
thyroid disease was highly common in patients with hyperthyroidism (68.2%) and hypothyroidism
(75.7%) (Figure 1).
J. Clin. Med. 2019, 8, 1142 4 of 11
Figure 1. Classification of study subjects according to the presence of hyperthyroidism or
hypothyroidism. (a) Among 44 patients with hyperthyroidism, 9 (20.4%) were confirmed to have
Graves’ disease, and 5 (11.4%) were confirmed to have transient thyrotoxicosis. (b) Among 218 patients
with hypothyroidism, 53 (24.3%) were confirmed to have primary hypothyroidism. The remaining
patients had central hypothyroidism.
3.2. Prevalence of Thyroid Disease According to Sex
The characteristics of the study patients are shown in Table 1. Upon classification according
to sex, the average age was higher in men than in women (p < 0.001). The prevalence rates of
nonfunctioning pituitary adenomas (NFPAs) and GH-secreting pituitary adenomas were higher in men
than in women; contrastingly, the prevalence rates of prolactin (PRL)-secreting pituitary adenomas
and adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas were higher in women than
in men (all p < 0.05, Table 1).
Table 1. Characteristics of the study population and prevalence of thyroid disease.
Total Male Female p Value
(n = 2202) (n = 885) (n = 1317)
Age (year) 45.0 ± 13.5 47.4 ± 13.7 44.3 ± 13.2 <0.001
Type of pituitary tumor
NFPA 1167 (53.0) 521 (58.9) 646 (49.1) <0.001
GH 488 (22.2) 223 (25.2) 265 (20.1) 0.005
PRL 209 (9.5) 19 (2.1) 190 (14.4) <0.001
ACTH 121 (5.5) 22 (2.5) 99 (7.5) <0.001
TSH 28 (1.3) 12 (1.4) 16 (1.2) 0.772
RCC 92 (4.2) 37 (4.2) 55 (4.2) 0.996
Craniopharyngioma 51 (2.3) 27 (3.1) 24 (1.8) 0.060
aOthers 46 (2.1) 24 (2.7) 22 (1.7) 0.094
Hyperthyroidism, n (%) 44 (2.0) 14 (1.6) 30 (2.3) 0.253
Primary, n (%) 14 (0.7) 2 (0.2) 12 (1.0) 0.056
Central, n (%) 30 (1.4) 12 (1.4) 18 (1.4) 0.904
Hypothyroidism, n (%) 218 (9.9) 102 (11.5) 116 (8.8) 0.036
Primary, n (%) 53 (2.5) 16 (1.8) 37 (3.0) 0.103
Central, n (%) 165 (7.8) 86 (9.8) 79 (6.3) 0.003
Post-thyroidectomy status, n (%) 74 (3.4) 11 (1.2) 63 (4.8) <0.001
Cancer, n (%) 59 (2.7) 10 (1.1) 49 (3.7) <0.001
Benign nodule, n (%) 11 (0.5) 0 (0.0) 11 (0.8) 0.004
Unknown reason, n (%) 4 (0.2) 1 (0.1) 3 (0.2) >0.999
Data are expressed as means ± standard deviations for normally distributed continuous variables and
as numbers (%) for categorical variables. Abbreviations: NFPA: nonfunctioning pituitary adenoma; GH:
growth hormone-secreting pituitary adenoma (including GH and PRL co-secreting pituitary adenoma); PRL:
prolactin-secreting pituitary adenoma; ACTH: adrenocorticotropic hormone-secreting pituitary adenoma; TSH:
thyroid-stimulating hormone-secreting pituitary adenoma (including GH and TSH co-secreting pituitary adenoma);
RCC: Rathke’s cleft cyst. aOthers: Chordoma, tumors metastatic to the pituitary gland, lymphocytic hypophysitis,
meningioma, germinoma, etc.
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The prevalence of hyperthyroidism was similar in men and women; however, central
hypothyroidism was significantly more common in men than in women. Among the 74 patients
with post-thyroidectomy status, 59 had thyroid cancer, and 11 had benign nodules; the reasons for
undergoing surgery were unclear (no available data) for four patients. Except for 21 patients who
underwent thyroid surgery at other hospitals, for whom no information on histological type was
available, almost all patients had papillary thyroid carcinomas (n = 35). There were two follicular
thyroid carcinoma patients and one double primary (papillary thyroid carcinoma + medullary thyroid
carcinoma) carcinoma patient. The most common histological type (94.9%) in Korea is papillary
carcinoma (94.9%) [13], and there was no specific thyroid cancer type associated with pituitary tumors.
The prevalence of post-thyroidectomy status was significantly higher in women than in men (Table 1).
3.3. Prevalence of Thyroid Disease According to Age
Upon classification according to age, hyperthyroidism was more common in younger patients
than in older patients. Furthermore, the prevalence of central hyperthyroidism was significantly
different between younger and older patients (p for trend = 0.039, Table 2). Hypothyroidism was more
common in older patients than in younger patients. The prevalence rates of both primary and central
hypothyroidism increased significantly with age. The prevalence of post-thyroidectomy status did not
differ according to age.
Table 2. Prevalence of thyroid disease according to age.
Total ~39 40~59 60~ p for Trend
(n = 2202) (n = 802) (n = 1058) (n = 342)
Hyperthyroidism, n (%) 44 (2.0) 21 (2.6) 22 (2.1) 1 (0.3) 0.017
Primary, n (%) 14 (0.6) 6 (0.7) 8 (0.8) 0 0.231
Central, n (%) 30 (1.4) 15 (1.9) 14 (1.3) 1 (0.3) 0.039
Hypothyroidism, n (%) 218 (9.9) 54 (6.7) 114 (10.8) 50 (14.5) <0.001
Primary, n (%) 53 (2.4) 12 (1.5) 26 (2.5) 15 (4.4) 0.005
Central, n (%) 165 (7.5) 42 (5.2) 88 (8.3) 35 (10.2) 0.001
Post-thyroidectomy status, n (%) 74 (3.4) 19 (2.4) 42 (4.0) 13 (3.8) 0.108
Cancer, n (%) 59 (2.7) 16 (2.0) 32 (3.0) 11 (3.2) 0.165
Benign nodule, n (%) 11 (0.5) 2 (0.2) 8 (0.8) 1 (0.3) 0.573
Unknown reason, n (%) 4 (0.2) 1 (0.1) 2 (0.2) 1 (0.3) 0.547
Data are expressed as numbers (%) for categorical variables.
3.4. Prevalence of Thyroid Disease According to the Type of Pituitary Disease
The prevalence of thyroid disease according to the type of pituitary disease is shown in Table 3.
As expected, central hyperthyroidism was closely related to TSH-secreting tumors. Two patients
were found to have TSH-secreting pituitary adenomas after total thyroidectomy for thyroid cancer.
These two patients had undergone thyroidectomy 4 months and 12 years before TSA. They showed
no clinical manifestations of TSH suppression, despite receiving increased doses of thyroid hormone.
TSH-secreting pituitary adenomas were confirmed by further evaluation.
In total, the pituitary pathologic samples from 134 (6.1%) patients showed positive results for
TSH. Among these patients, only 26 (19.4%) exhibited the clinical features of central hyperthyroidism.
Positive TSH staining was also observed in 1/14 cases of primary hyperthyroidism, 2/53 cases of
primary hypothyroidism, 4/165 cases of central hypothyroidism, and 2/74 cases of post-thyroidectomy
status. Among the 30 patients with confirmed central hyperthyroidism, 26 showed positive results for
TSH. However, the central hyperthyroidism pattern was also observed in four cases with negative
TSH staining.
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Table 3. Prevalence of thyroid disease according to the type of pituitary disease.
Total NFPA GH PRL ACTH TSH RCC Craniopharyngioma Others a p-Value
(n = 2202) (n = 1167) (n = 488) (n = 209) (n = 121) (n = 28) (n = 92) (n = 51) (n = 46)
Hyperthyroidism, n (%) 44 (2.0) 12 (1.0) 5 (1.0) 1 (0.5) 0 26 (92.9) 0 0 0 <0.001
Primary, n (%) 14 (0.7) 9 (0.8) 5 (1.0) 0 0 0 0 0 0 0.660
Confirmed as Graves’ disease 9 (0.4) 8 (0.7) 1 (0.2)
Confirmed as transient thyrotoxicosis 5 (0.2) 1 (0.1) 4 (0.8)
Central, n (%) 30 (1.4) 3 (0.3) 0 1 (0.5) 0 26 (92.9) 0 0 0 <0.001
Hypothyroidism, n (%) 218 (9.9) 147 (12.6) 9 (1.8) 7 (3.3) 18 (14.9) 0 16 (17.4) 11 (21.6) 10 (21.7) <0.001
Primary, n (%) 53 (2.5) 40 (3.4) 2 (0.4) 3 (1.4) 3 (2.5) 0 1 (1.1) 1 (2.0) 3 (6.5) 0.008
Central, n (%) 165 (7.8) 107 (9.2) 7 (1.4) 4 (1.9) 15 (12.4) 0 15 (16.3) 10 (19.6) 7 (15.2) <0.001
Post-thyroidectomy status, n (%) 74 (3.4) 26 (2.2) 27 (5.5) 10 (4.8) 4 (3.3) 2 (7.1) 1 (1.1) 1 (2.0) 3 (6.5) 0.014
Cancer, n (%) 59 (2.7) 19 (1.6) 21 (4.3) 9 (4.3) 3 (2.5) 2 (7.1) 1 (1.1) 1 (2.0) 3 (6.5) 0.012
Benign nodule, n (%) 11 (0.5) 5 (0.4) 5 (1.0) 0 1 (0.8) 0 0 0 0 0.633
Unknown reason, n (%) 4 (0.2) 2 (0.2) 1 (0.2) 1 (0.5) 0 0 0 0 0 0.977
Data are expressed as numbers (%) for categorical variables Abbreviations: NFPA: nonfunctioning pituitary adenoma; GH: growth hormone-secreting pituitary adenoma (including GH
and PRL co-secreting pituitary adenoma); PRL: prolactin-secreting pituitary adenoma; ACTH: adrenocorticotropic hormone-secreting pituitary adenoma; TSH: thyroid-stimulating
hormone-secreting pituitary adenoma (including GH and TSH co-secreting pituitary adenoma); RCC: Rathke’s cleft cyst a Chordoma, tumors metastatic to the pituitary gland, lymphocytic
hypophysitis, meningioma, germinoma, etc.
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The prevalence of pituitary disease differed according to age and sex. Therefore, its frequency
was analyzed after adjusting for age and sex. Central hypothyroidism was more common in patients
with ACTH-secreting pituitary adenomas (aOR 1.85, 95% CI 1.01–3.37), Rathke’s cleft cysts (aOR 2.34,
95% CI 1.27–4.32), and craniopharyngiomas (aOR 2.58, 95% CI 1.24–5.35; Figure 2) than in those with
NFPAs, after adjusting for age and sex. Contrarily, thyroid cancer had an increased prevalence in
patients with GH-secreting pituitary adenomas (aOR 3.17, 95% CI 1.67–6.02), PRL-secreting pituitary
adenomas (aOR 3.66, 95% CI 1.45–9.28), and TSH-secreting pituitary adenomas (aOR 6.28, 95% CI
1.34–29.36) (Figure 2).
Figure 2. The concurrence rate and odds ratios of central hypothyroidism and thyroid cancer according
to type of pituitary disease. Multiple logistic regression analysis was performed to evaluate the
concurrent risk of (a) central hypothyroidism and (b) thyroid cancer. The multiple logistic regression
model was adjusted for age and sex. Abbreviations: NFPA: nonfunctioning pituitary adenoma; GH:
growth hormone-secreting pituitary adenoma (including GH and PRL co-secreting pituitary adenoma);
PRL: prolactin-secreting pituitary adenoma; ACTH: adrenocorticotropic hormone-secreting pituitary
adenoma; TSH: thyroid-stimulating hormone-secreting pituitary adenoma (including GH and TSH
co-secreting pituitary adenoma); RCC: Rathke’s cleft cyst. * p-values < 0.05.
4. Discussion
Thyroid disorders are mainly caused by the thyroid itself but are occasionally caused by pituitary
disease. Although the treatment and prognosis of these disorders differ according to their causes, it is
difficult to distinguish between the two causes, especially when these disorders occur together. In this
study, we found that over 20% of thyroid disorders were primary thyroid disorders that occurred with
pituitary disease. In addition, the prevalence of central hypothyroidism was higher in patients with
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ACTH-secreting pituitary adenomas, Rathke’s cleft cysts, and craniopharyngiomas than in those with
NFPAs. Contrastingly, thyroid cancer showed an increased prevalence in patients with GH-, PRL-, and
TSH-secreting pituitary adenomas.
In this study, pituitary disease was accompanied by hyperthyroidism, hypothyroidism, and
post-thyroidectomy status in 2%, 9.9%, and 3.4% of patients, respectively. The prevalence rates of
thyroid-origin thyroid diseases such as primary hyperthyroidism, primary hypothyroidism, and
thyroid cancer were 0.7%, 2.5%, and 2.7%, respectively. The prevalence rates of hyperthyroidism
and hypothyroidism have varied among various studies. According to the Korea National Health
and Nutrition Examination Survey conducted from 2013 to 2015, the prevalence rates of overt
hyperthyroidism and hypothyroidism were 0.5% and 0.7%, respectively [14]. For ease of comparison,
the prevalence of patients undergoing treatment for hypothyroidism and hyperthyroidism in the
Korean general population in 2015 is shown in Table S1 [15] (0.3% for hyperthyroidism and 1.6% for
hypothyroidism). Considering that the 5-year prevalence rate of thyroid cancer has not exceeded
1% in the whole Korean population (based on the 2016 survey) [16], the prevalence rates of primary
hyperthyroidism, primary hypothyroidism, and thyroid cancer tended to be higher in our study
population than in those from previous general population studies. However, when comparing
the results of the current and previous studies, we need to consider the large differences in several
characteristics of the study population, such as age and gender. Because the national database provides
data that is based on results of screening thyroid function tests, the prevalence of thyroid disease may
be lower than that of pituitary disease.
Previous general population studies have reported high prevalence rates of hyperthyroidism in
women and older patients [14,15,17]. The prevalence of hyperthyroidism was also high in females
in this study. However, hyperthyroidism, especially central hyperthyroidism, was more common
in younger patients than in older patients in our study population. This might be related to the
incidence of TSH-secreting pituitary adenomas that mostly develop in the fifth and sixth decades of
life [18]. Previous general population studies showed that the prevalence of hypothyroidism was
greater in females and that it increased with age (Table S2) [14,15,17,19]. In our study, the prevalence
of hypothyroidism increased with age but was not greater in females. This may be explained by the
fact that macroadenomas are more common in men; therefore, men had high chances of developing
central hypothyroidism [20,21].
In our study, pathologic data on pituitary disease showed that samples from 134 (6.1%) patients
showed positive staining for TSH. However, most patients with positive TSH staining did not show
clinical features of central hyperthyroidism. This discrepancy seemed to be related to clinically
nonfunctioning or entrapped residual cells. Because pituitary disease often shows inconsistent
staining patterns and clinical features, pituitary disease is classified according to clinical function or
hormone production [22]. When we examined the differences in prevalence rates of thyroid disease
according to the type of pituitary disease, central hypothyroidism was more common in patients with
ACTH-secreting pituitary adenomas, Rathke’s cleft cysts, and craniopharyngiomas than in those with
NFPAs. In cases of ACTH-secreting pituitary adenomas, excess glucocorticoid levels could have caused
the blunted response of TSH [23]. Central hypothyroidism accompanied by Rathke’s cleft cysts [24] or
craniopharyngiomas [25] has often been reported. These lesions were thought to be larger than those
of other pituitary diseases at the time of surgery because of late detection; however, our obtained data
(without data on the size or extent of pituitary disease) were not relevant for pertinent analysis.
Contrastingly, thyroid cancer had higher prevalence rates in patients with GH-, PRL-, and
TSH-secreting pituitary adenomas. An increase in GH levels has been reported to be associated
with thyroid cancer and various carcinomas [6]. Acromegaly increases cancer risk, and there is
some evidence that GH and IGF-1 are important contributors to thyroid cancer in patients with
acromegaly [26]. Moreover, TSH-secreting pituitary adenomas with thyroid cancer have been reported
frequently [5]. A possible role of TSH hypersecretion in the development of thyroid tumors was
suggested in previous studies [27]. Tam et al. reported that patients with prolactinomas showed
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increased thyroid nodule frequency and thyroid volume, and increasing evidence is available on
the role of prolactin in the development of various cancers [28]; however, the relationship between
prolactin levels and cancer risk is still controversial.
There were several limitations in this study. First, we selected patients who underwent TSA at a
tertiary hospital, and this could have resulted in selection bias. However, research on a rare disease
is difficult with only general information, such as that provided by the National Health Information
database [29]. Second, this study was a cross-sectional study; therefore, a causal relationship could
not be assessed. In addition, a direct comparison of the prevalence of thyroid disorders between
the study and general populations was not suitable, considering the differences in the method of
investigation and the study population. Third, thyroid ultrasonography was routinely performed only
in patients with acromegaly. This could have resulted in underestimation of the prevalence of thyroid
cancer in patients with other types of pituitary diseases. Furthermore, information on detailed mass
size was not clear in the database of this study; thus, we could not analyze the relationship between
these parameters and central hypothyroidism. Finally, considering the design and disease definition
of this study, it was difficult to deal with the details of subclinical hyperthyroidism and subclinical
hypothyroidism that may be missed in medical history taking. Additionally, the possibility of other
causes other than thyroid or pituitary origin, including hypothalamic disorders or newly developed
thyroid disease following TSA, has been difficult to ascertain due to the limitations of our database.
This study was based on data collected up to the time of TSA; therefore, additional research is needed
on the risk of thyroid cancer after TSA.
Our study also has various strengths. We enrolled a large population of patients undergoing
TSA for pituitary disease over a 10-year period, and we evaluated the prevalence of thyroid disease
accompanied by pituitary disease, which is occasionally encountered in the clinical field, especially by
endocrine specialists. Furthermore, collection of thyroid function test data and pathologic confirmation
were possible because all patients had undergone surgery. In general, prevalence studies are conducted
on nationwide population-based cohorts [15]. However, pituitary disease is rare [30], and detailed
nationwide information is not available for the accompanying diseases. Our pituitary tumor center is
one of the largest and most representative pituitary tumor centers in Korea [17,31,32]. We analyzed
medical records and were able to obtain data that were more accurate than those from the National
Health Information database. Through this, we could confirm the association of thyroid disease with
various types of pituitary diseases. To our knowledge, this is the first study aimed at evaluating the
prevalence of thyroid disease in patients who underwent TSA for pituitary disease.
In conclusion, the prevalence of thyroid disease tended to be higher in our study than in previous
general population studies, and the prevalence varied according to the type of pituitary disease. We
should be aware that pituitary disease sometimes accompanies thyroid disease, and this accompanied
thyroid disease may have a different underlying cause than what was originally suspected [33].
Pituitary diseases may mask thyroid disorders, and focusing on the pituitary problem can neglect the
thyroid disease.
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